Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathilde Jalving

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2017
Theranostics Using Antibodies and Antibody-Related TherapeuticsKirsten L Moek, Danique Giesen, Iris C Kok, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 21, 2023
Pharmacological inhibition of MEK1/2 signaling disrupts bile acid metabolism through loss of Shp and enhanced Cyp7a1 expressionCristy R C Verzijl, Ivo P van de Peppel, Roos E Eilers, et al.
European Journal of Cancer (Oxford, England : 1990)|May 25, 2005
Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis inductionJan J Koornstra, Mathilde Jalving, Fleur E M Rijcken, et al.
Elife|May 13, 2025
Transcriptional pattern enriched for synaptic signaling is associated with shorter survival of patients with high-grade serous ovarian cancerArkajyoti Bhattacharya, Thijs S Stutvoet, Mirela Perla, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatmentWellington Candido, Annemarie Cecile Eggen, Mathilde Jalving, et al.
JACC. Advances|November 25, 2024
Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors: Data From a Prospective StudyPieter F van den Berg, Valentina Bracun, Michel Noordman, et al.
Cancers|March 25, 2022
Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian CancerChris J de Witte, Joachim Kutzera, Arne van Hoeck, et al.
The Lancet Regional Health. Europe|October 29, 2025
Longitudinal data on advanced cutaneous squamous cell carcinoma from the Dutch Keratinocyte Cancer Collaborative (DKCC): a nationwide real-world database studyLoes M Hollestein, Celeste J Eggermont, Marieke W J Louwman, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 2, 2021
Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapyPim P van de Donk, Thijs T Wind, Jahlisa S Hooiveld-Noeken, et al.
Oncoimmunology|February 7, 2019
A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanomaThijs T Wind, Mathilde Jalving, Jacco J de Haan, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2017
Theranostics Using Antibodies and Antibody-Related TherapeuticsKirsten L Moek, Danique Giesen, Iris C Kok, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 21, 2023
Pharmacological inhibition of MEK1/2 signaling disrupts bile acid metabolism through loss of Shp and enhanced Cyp7a1 expressionCristy R C Verzijl, Ivo P van de Peppel, Roos E Eilers, et al.
European Journal of Cancer (Oxford, England : 1990)|May 25, 2005
Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis inductionJan J Koornstra, Mathilde Jalving, Fleur E M Rijcken, et al.
Elife|May 13, 2025
Transcriptional pattern enriched for synaptic signaling is associated with shorter survival of patients with high-grade serous ovarian cancerArkajyoti Bhattacharya, Thijs S Stutvoet, Mirela Perla, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatmentWellington Candido, Annemarie Cecile Eggen, Mathilde Jalving, et al.
JACC. Advances|November 25, 2024
Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors: Data From a Prospective StudyPieter F van den Berg, Valentina Bracun, Michel Noordman, et al.
Cancers|March 25, 2022
Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian CancerChris J de Witte, Joachim Kutzera, Arne van Hoeck, et al.
The Lancet Regional Health. Europe|October 29, 2025
Longitudinal data on advanced cutaneous squamous cell carcinoma from the Dutch Keratinocyte Cancer Collaborative (DKCC): a nationwide real-world database studyLoes M Hollestein, Celeste J Eggermont, Marieke W J Louwman, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 2, 2021
Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapyPim P van de Donk, Thijs T Wind, Jahlisa S Hooiveld-Noeken, et al.
Oncoimmunology|February 7, 2019
A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanomaThijs T Wind, Mathilde Jalving, Jacco J de Haan, et al.
Pageof 8